News | 10 November 2022
Lupin Q2 FY2023 revenue remains flat
Investment in R&D was Rs. 337.6 crore (8.3% of sales) for Q2 FY2023 as compared to Rs. 330 crore (8.2% of sales) for Q2 FY2022.
Investment in R&D was Rs. 337.6 crore (8.3% of sales) for Q2 FY2023 as compared to Rs. 330 crore (8.2% of sales) for Q2 FY2022.
The core of “LANXESS Biosecurity Solutions” is a portfolio of scientifically formulated, highly effective and versatile biocidal products
The Group will continue to make proactive investments of its management resources in the life science business
For the half year ended September 30th, 2022 revenue from operations stood at Rs. 185.44 crore in H1 FY23, as against Rs. 219.89 crore in H1 FY22, a decrease of 15.67%
The company has successfully developed Methyl salicylate using Flow Chemistry and successfully erected a Flow reactor at Jhagadia plant and expects to start production from Q3 FY23
The company posted net profit of Rs.81.33 crores for the quarter ended September 30, 2021.
The acquisition is for an enterprise value of Rs. 218 crores
R&D center would be doing a lot of new product generation projects, process optimization, scale-up and product life cycle management work, full synthetic labs, the kilo labs, the process safety labs, and the population lab
Revenue from operations for the half year was Rs. 178.5 crore, declined by 23% whereas net profit for the half year was Rs. 16.9 crore, declined by 70%
Pantoprazole Sodium Sesquihydrate are proton pump inhibitors used in drugs to suppress the gastric acid secretion
Revenue is up 23% whereas Profit After Tax expands 29% for the company
H1 FY23 revenues at Rs. 860.1 crore, higher by 40% YoY whereas PAT at Rs. 52.6 crore, higher by 4% YoY
Saroglitazar Mg is an investigational compound in the USA/EU, undergoing Phase 2b/3 clinical trials in patients with Primary Biliary Cholangitis and Phase 2b in patients with Non- alcoholic Steatohepatitis
The company has reported total income of Rs. 799.52 crores during the period ended September 30, 2022
The company has reported total income of Rs. 77.60 crores during the period ended September 30, 2022
The company has reported total income of Rs. 703.3 crores during the period ended September 30, 2022
Innovative Capsugel Enprotect capsule can simplify the manufacturing process to accelerate drug development and expedite first-in-human timelines
API platform to comprise of RA Chem Pharma, ZCL Chemicals and Avra Laboratories
Through the collaboration, Lonza will gain access to Singzyme’s enzymatic conjugation platform enabling the site-specific binding of payloads with peptidic linkers to proteins of interest
Subscribe To Our Newsletter & Stay Updated
